作者
Steven R Steinhubl, J David Talley, Gregory A Braden, James E Tcheng, Peter J Casterella, David J Moliterno, Frank I Navetta, Peter B Berger, Jeffrey J Popma, George Dangas, Richard Gallo, David C Sane, Jorge F Saucedo, Gang Jia, A Michael Lincoff, Pierre Theroux, David R Holmes, Paul S Teirstein, Dean J Kereiakes
发表日期
2001/5/29
期刊
Circulation
卷号
103
期号
21
页码范围
2572-2578
出版商
Lippincott Williams & Wilkins
简介
Background—The optimal level of platelet inhibition with a glycoprotein (GP) IIb/IIIa antagonist necessary to minimize thrombotic complications in patients undergoing a percutaneous coronary intervention (PCI) is currently unknown.
Methods and Results—Five hundred patients undergoing a PCI with the planned use of a GP IIb/IIIa inhibitor had platelet inhibition measured at 10 minutes, 1 hour, 8 hours, and 24 hours after the initiation of therapy with the Ultegra Rapid Platelet Function Assay (Accumetrics). Major adverse cardiac events (MACEs: composite of death, myocardial infarction, and urgent target vessel revascularization) were prospectively monitored, and the incidence correlated with the measured level of platelet function inhibition at all time points. One quarter of all patients did not achieve ≥95% inhibition 10 minutes after the bolus and experienced a significantly higher incidence of MACEs (14.4 …
引用总数
学术搜索中的文章
SR Steinhubl, JD Talley, GA Braden, JE Tcheng… - Circulation, 2001
